This competition is closed. All submitted proposals will be assessed according to the process outlined in the competition timeline, and results will be announced as indicated.
Ontario Genomics is pleased to announce that Genome Canada, in partnership with the Canadian Institutes of Health Research (CIHR), is seeking proposals for research projects to address any aspect of bioinformatics and computational biology (B/CB) as it relates to genomics. Proposals with applications across all of Genome Canada’s sectors are welcome. These include agriculture & agri-food, fisheries & aquaculture, forestry, energy, environment, human health and mining.
Genome Canada has identified B/CB as a priority area with the goal to create an environment that supports the creation and evolution of enhanced B/CB tools and methodologies. In August 2015, a B/CB Advisory Committee struck by Genome Canada and CIHR released a consultative version of a Strategic Framework for the future of B/CB in Canada. This competition builds on Genome Canada’s 2012 B/CB competition, also in partnership with CIHR, and seeks to advance the objectives of the proposed B/CB national strategy.
The major objectives of this Request for Applications (RFA) are to:
- Support the development of next generation Bioinformatics and Computational Biology tools and methodologies that will be required by the research community to deal with the influx of large amounts of data produced by modern genomics technologies; and,
- Provide broad access of these new Bioinformatics and Computational Biology tools to the research community.
CIHR is partnering on this RFA in support of proposals in the area of human health because it recognizes that application of current technologies in genomics would create health-related data sets of unprecedented size and complexity, such that advanced computational tools are required for their analysis.
UPDATED There is $5 million of federal funding available for this competition, including $2 million through Genome Canada, $2 million through CIHR’s Roadmap Accelerator Fund (RAF)1 and $1 million through CIHR’s Institute of Musculoskeletal Health and Arthritis (IMHA)2. There will be a maximum investment of $250,000 per project for up to 2 years. Co-funding is NOT required.
In order to better prepare Ontario-led projects for this competition, Ontario Genomics will do an initial eligibility assessment of registrations and will coordinate an external review of eligible applications prior to submission to Genome Canada. Please note that to accommodate this process the deadlines for submission to Ontario Genomics differ from those in the official RFA from Genome Canada. Eligible applicants will receive feedback on their applications including gaps and areas for improvement.
Researchers in Ontario intending to submit an application are strongly encouraged to contact Ontario Genomics to discuss details of the competition such as the scope and application process.
Application Material and Relevant Links
Full Application forms:
2015 B/CB Application Form – UPDATED
|October 29, 2015||Launch of Request for Applications (RFA)|
|November 30, 2015 (12:00PM)||Draft Registrations due to Ontario Genomics (submit forms to email@example.com)|
|December 9, 2015 (12:00PM)||Final Registrations due to Ontario Genomics* (submit forms to firstname.lastname@example.org)|
|December 11, 2015||Eligible registrations due to Genome Canada|
|December 18, 2015||Review of eligibility of registrations by Genome Canada completed|
|January 28, 2016
||Draft Full Applications due to Ontario Genomics (submit forms to email@example.com)|
|February 25, 2016
||Final Full Applications due to Ontario Genomics (submit forms to firstname.lastname@example.org)|
|March 4, 2016||Deadline for Full Applications to Genome Canada|
|Early May, 2016||Review process completed|
|Late June, 2016||Decisions by Genome Canada and Partners|
|Late June, 2016||Notification of Decision|
*Ontario Genomics does not require institutional signatures on final registrations, but institutional requirements may vary, so please check with your institution.
1 CIHR’s RAF is intended to support transformative and impactful research that aligns with CIHR’s Research Priorities and is multi-disciplinary in nature. Scientific leadership and support for this RAF-funded initiative is shared across CIHR’s Institute of Cancer Research (ICR), Institute of Genetics (IG), and Institute of Infection and Immunity (III).
2 CIHR’s IMHA is intended to support applications that align with its relevant research areas: Chronic Pain and Fatigue, Inflammation and Tissue Repair and Disability, Mobility and Health. CIHR-IMHA supports research to enhance active living, mobility and movement, and oral health; and addresses causes, prevention, screening, diagnosis, treatment, support systems, and palliation for a wide range of conditions related to bones, joints, muscles, connective tissue, skin and teeth.